LDE.F Landec Corporation
- Market cap
- EUR 214M
- P/E
- -
- P/B
- 203.86x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Aug 2026.
Is LDE.F undervalued?
Graham numberThe Graham number of Landec Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Landec Corporation fundamental analysis
No fundamental analysis for Landec Corporation yet.
Landec Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Landec Corporation
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company a…
Full company profileLandec Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 4 quarters up to Aug 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Landec Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 541M | 532M | 524M | 558M | 590M | 544M | 186M | 103M | 128M | 129M | 114M |
| Gross Profit | 71.0M | 83.2M | 78.3M | 81.0M | 75.0M | 81.5M | 50.6M | 27.3M | 41.9M | 40.3M | 31.2M |
| Operating Income | 14.2M | 18.1M | 13.6M | 5.48M | -8.30M | 5.89M | 81.0K | -24.0M | -7.19M | -12.0M | -6.07M |
| EBITDA | - | 27.5M | 30.8M | 24.1M | -22.9M | -5.26M | -16.9M | -37.0M | 35.6M | -8.48M | -32.0M |
| Net Income | -11.6M | 10.6M | 24.8M | 411K | -38.2M | -32.7M | -97.2M | -102M | 12.0M | -38.7M | -71.2M |
| EPS | - | 0.39 | 0.90 | 0.01 | -1.31 | -1.11 | -3.29 | -3.46 | 0.39 | -1.05 | -1.88 |
| Balance Sheet | |||||||||||
| Total Assets | 343M | 359M | 405M | 519M | 541M | 503M | 295M | 255M | 254M | 239M | 228M |
| Total Liabilities | 131M | 130M | 152M | 249M | 310M | 300M | 187M | 257M | 243M | 238M | 302M |
| Shareholders' Equity | 211M | 227M | 253M | 270M | 231M | 203M | 108M | -1.84M | 11.3M | 1.34M | -73.4M |
| Cash & Short-term Investments | 9.89M | 5.41M | 2.90M | 1.08M | 360K | 1.30M | 1.64M | 19.1M | 8.46M | 8.27M | 23.0M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.9M | 29.8M | 19.8M | 16.0M | -17.0M | 15.0M | -24.4M | -34.5M | 257K | -206K | 27.8M |
| Capital Expenditure | 40.9M | 23.0M | 33.6M | 44.7M | 26.7M | 23.8M | 28.1M | 20.8M | 18.4M | 13.4M | 3.65M |
| Free Cash Flow | - | 6.74M | -13.8M | -28.7M | -43.7M | -8.75M | -52.5M | -55.2M | -18.1M | -13.6M | 24.1M |
| Ratios | |||||||||||
| ROE | -5.5% | 4.7% | 9.8% | 0.2% | -16.5% | -16.1% | -89.9% | - | 106.2% | -2,898.0% | - |
| ROA | -3.4% | 3.0% | 6.1% | 0.1% | -7.1% | -6.5% | -32.9% | -40.1% | 4.7% | -16.2% | -31.2% |
| Net Profit Margin | -2.2% | 2.0% | 4.7% | 0.1% | -6.5% | -6.0% | -52.3% | -99.0% | 9.4% | -30.0% | -62.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Landec Corporation dividends
Landec Corporation has not paid dividends in the last 9 fiscal years.
Who owns Landec Corporation
- Insiders 3.04%
- Institutions 72.53%
- Public & others 24.43%
- Shares outstanding 37.9M
- Free float 19.6M
Landec Corporation company profile
- Company name
- Landec Corporation
- Ticker
- LDE.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 382
- Fiscal year end
- May
- Address
- 3515 Lyman Boulevard, Chaska, MN, United States, 55318
- Phone
- 952 368 4300
- Website
- lifecore.com
About Landec Corporation
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
Landec Corporation management
8- Mr. Paul JosephsPresident, CEO & Director · born 1965
- Mr. Ryan D. Lake CPAExecutive VP & CFO · born 1977
- Mr. Thomas D. SalusChief Legal & Administration Officer and Corporate Secretary · born 1969
- Mr. Thomas GuldagerVice President of Operations
- Mr. Aaron PerlitshDirector of Internal Audit & Chief Compliance Officer
- Ms. Jackie Q. KleckerExecutive Vice President of Quality & Development Services
- Mr. Mark DaFonsecaChief Commercial Officer
- Mr. Parker K. JavidVice President · born 1969